Here, we identified that CXCR4 acted as an oncogene to promote cancer progression and genetically silencing of CXCR4 increased cisplatin (DDP)-sensitivity in ccRCC in vitro and in vivo. This evidence concerns the gene CXCR4 and nonpapillary renal cell carcinoma.